Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use

Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use

In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability in a real-life setting. A single-center observational s...

Full description

Bibliographic Details
Main Authors: Cosmo Del Borgo, Silvia Garattini, Carolina Bortignon, Anna Carraro, Daniela Di Trento, Andrea Gasperin, Alessandra Grimaldi, Sara Giovanna De Maria, Sara Corazza, Tiziana Tieghi, Valeria Belvisi, Blerta Kertusha, Margherita De Masi, Ombretta D’Onofrio, Gabriele Bagaglini, Gabriella Bonanni, Paola Zuccalà, Paolo Fabietti, Eeva Tortellini, Mariasilvia Guardiani, Alessandra Spagnoli, Raffaella Marocco, Danilo Alunni Fegatelli, Miriam Lichtner, LATINA COVID-group
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Viruses
Subjects:
antivirals
molnupiravir
remdesivir
nirmaltrelvir/ritonavir
early therapy
COVID-19
Online Access:https://www.mdpi.com/1999-4915/15/4/1025

Internet

https://www.mdpi.com/1999-4915/15/4/1025

Similar Items